ENDOPROTECH, INC.

Basic Information

1044 E CHESTNUT ST
LOUISVILLE, KY, 40204-1019

Company Profile

n/a

Additional Details

Field Value
DUNS: 144667602
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Device for Delivery of Rolipram to Liver for Treatment of Alcoholic Liver Disease

    Amount: $277,707.00

    DESCRIPTION (provided by applicant): Alcoholic Liver Disease (ALD) remains a leading cause of death from liver disease in the U.S., and there is still no FDA-approved therapy. Abnormal cytokine metabo ...

    SBIR Phase I 2012 Department of Health and Human Services
  2. New anti-complement therapy to reduce reperfusion injury: Phase II

    Amount: $963,666.00

    DESCRIPTION (provided by applicant): Tissue and organ transplantation procedures save and/or improve the lives of hundred of thousands of patients annually in the US. The goal of this research is to d ...

    STTR Phase II 2008 Department of Health and Human Services
  3. New anti-complement therapy to reduce reperfusion injury

    Amount: $122,978.00

    DESCRIPTION (provided by applicant): The purpose of this proposal is to provide proof-of-concept that a novel therapy that prevents complement activation could be effective in reducing ischemia rep ...

    STTR Phase I 2005 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government